ArticleTranslational cancer research2026
Prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal carcinoma: a systematic review and meta-analysis of 30 cohorts through June 30, 2026.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous meta-analyses have linked an elevated pretreatment neutrophil-to-lymphocyte ratio (NLR) to poor outcomes in nasopharyngeal carcinoma (NPC), but they included few recent cohorts and often combined adjusted and unadjusted estimates. We updated the evidence base and evaluated the consistency and certainty of the associations between pretreatment NLR and survival outcomes. Methods: We systematically searched PubMed, Web of Science, Embase, the Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Data from inception through June 30, 2026. Eligible reports were cohort studies of pathologically confirmed NPC that compared high versus low pretreatment NLR and reported multivariable-adjusted hazard ratios (HRs) for overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), or locoregional recurrence-free survival (LRFS). Two reviewers independently selected studies, extracted data, and assessed risk of bias using the Newcastle-Ottawa Scale (NOS). Random-effects models, prespecified subgroup analyses, leave-one-out analyses, assessment of small-study effects, and Grading of Recommendations Assessment, Development and Evaluation (GRADE) certainty assessment were used. Results: Thirty cohorts comprising 11,671 patients were included; NOS scores ranged from 7 to 9. Elevated pretreatment NLR was associated with inferior OS [27 cohorts; HR: 2.16, 95% confidence interval (CI): 1.76-2.66] and PFS (18 cohorts; HR: 1.70, 95% CI: 1.45-2.00). Furthermore, high NLR correlated with compromised DMFS (6 cohorts; HR: 1.61, 95% CI: 1.33-1.93) and LRFS (2 cohorts; HR: 4.82, 95% CI: 1.51-15.31). Heterogeneity was substantial for OS (I Conclusions: Elevated pretreatment NLR was associated with poorer survival outcomes in NPC. However, substantial heterogeneity, evidence of small-study effects for OS, and low to very low certainty of evidence preclude routine clinical implementation. Prospective validation using standardized sampling and cutoff methods is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.